Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Editas Medicine (EDIT)

Editas Medicine (EDIT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 198,941
  • Shares Outstanding, K 82,548
  • Annual Sales, $ 78,120 K
  • Annual Income, $ -153,220 K
  • EBIT $ -229 M
  • EBITDA $ -227 M
  • 60-Month Beta 2.01
  • Price/Sales 2.62
  • Price/Cash Flow N/A
  • Price/Book 1.17

Options Overview Details

View History
  • Implied Volatility 119.23% ( -2.03%)
  • Historical Volatility 79.38%
  • IV Percentile 91%
  • IV Rank 65.96%
  • IV High 161.87% on 04/29/24
  • IV Low 36.62% on 05/30/24
  • Put/Call Vol Ratio 0.06
  • Today's Volume 898
  • Volume Avg (30-Day) 709
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 35,088
  • Open Int (30-Day) 35,409

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.43
  • Number of Estimates 10
  • High Estimate 0.48
  • Low Estimate -1.05
  • Prior Year -0.23
  • Growth Rate Est. (year over year) -86.96%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.30 +3.04%
on 11/21/24
3.75 -36.80%
on 10/22/24
-1.39 (-36.97%)
since 10/21/24
3-Month
2.30 +3.04%
on 11/21/24
4.12 -42.48%
on 09/18/24
-1.71 (-41.91%)
since 08/21/24
52-Week
2.30 +3.04%
on 11/21/24
11.69 -79.73%
on 12/06/23
-7.75 (-76.58%)
since 11/21/23

Most Recent Stories

More News
1 Penny Stock to Grab Now for 183% Upside Potential

This biotech penny stock could more than triple, based on consensus forecasts.

VRTX : 450.37 (-0.19%)
EDIT : 2.37 (-1.66%)
BMY : 58.23 (+0.60%)
Editas Medicine to Participate in Upcoming Investor Conferences

EDIT : 2.37 (-1.66%)
Editas: Q3 Earnings Snapshot

Editas: Q3 Earnings Snapshot

EDIT : 2.37 (-1.66%)
Editas Medicine Announces Third Quarter 2024 Results and Business Updates

EDIT : 2.37 (-1.66%)
Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update

EDIT : 2.37 (-1.66%)
Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics

EDIT : 2.37 (-1.66%)
Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept

EDIT : 2.37 (-1.66%)
Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust

EDIT : 2.37 (-1.66%)
Looking for Stock Bargains With Room to Run? Try This.

Investing tips from Bill Mann, The Motley Fool's director of small-cap research.

WBA : 8.30 (+0.73%)
AAPL : 228.52 (-0.21%)
AMZN : 198.38 (-2.22%)
EXPE : 183.51 (+2.46%)
DENN : 6.39 (+1.91%)
CBRL : 47.64 (+2.74%)
JACK : 47.80 (+4.82%)
BJRI : 34.52 (+1.14%)
SABR : 3.67 (+1.94%)
EDIT : 2.37 (-1.66%)
CRSP : 46.29 (-2.05%)
DESP : 18.49 (+4.40%)
Editas: Q2 Earnings Snapshot

Editas: Q2 Earnings Snapshot

EDIT : 2.37 (-1.66%)

Business Summary

Editas Medicine is a development-stage genome editing biotech, which makes medicines to treat serious diseases using its proprietary genome editing platform based on the unique Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. Though the company's discovery efforts target...

See More

Key Turning Points

3rd Resistance Point 2.63
2nd Resistance Point 2.55
1st Resistance Point 2.46
Last Price 2.37
1st Support Level 2.29
2nd Support Level 2.21
3rd Support Level 2.12

See More

52-Week High 11.69
Fibonacci 61.8% 8.10
Fibonacci 50% 6.99
Fibonacci 38.2% 5.89
Last Price 2.37
52-Week Low 2.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar